Omnicell, Inc. (Nasdaq: OMCL) (“Omnicell” or the “Company”), a leader in transforming the pharmacy care delivery model, yesterday announced that the Board of Directors elected Eileen Voynick to the Board, effective January 5, 2024. Ms. Voynick fills the vacancy resulting from Sara J. White, a Class I director who stepped down from the Company’s Board of Directors, effective January 5, 2024. In addition, the Company announced that Vance Moore will not stand for reelection to the Company’s Board at Omnicell’s 2024 annual meeting of stockholders (the “2024 annual meeting”) and effective as of the 2024 annual meeting, the size of the Board will be reduced from ten to nine directors.
Ms. Voynick brings over three decades of experience driving sales and operations at global industry leaders, including in the healthcare technology industry, at the executive and board level. She most recently served as Chief Executive Officer of Sparta Systems Inc., a leading provider of enterprise-quality management software solutions. Prior to Sparta Systems, Ms. Voynick served as Chief Operating Officer at Allscripts Healthcare Solutions, Inc. (n/k/a Veradigm Inc., Nasdaq: MDRX), as Executive Vice President of global sales, services, and support at Misys Healthcare Systems, and in various management positions at Oracle, SAP, Siebel Systems, Gartner, Ariba, and Accenture. Ms. Voynick is currently board chair of AGS Health LLC, a revenue cycle management provider, and has held board positions for several other organizations, including Skydeck Acquisition Corp. (former Nasdaq: SKYAU), CDK Global, Inc. (former Nasdaq: CDK), r3, Advanced MD Health, Jefferson Health, Philadelphia University and Thomas Jefferson University.
“We are pleased to welcome Eileen to the Omnicell Board of Directors,” said Randall Lipps, chairman, president, chief executive officer, and founder of Omnicell. “Eileen is a widely respected leader with significant experience in the software, technology, and healthcare industries, as well as a proven track record creating value for stockholders, accelerating growth, driving operational excellence, and developing global businesses. I am confident that her skills will complement and strengthen our Board as Omnicell continues to focus on driving long-term value and delivering outcome-centric innovations to improve patient outcomes.”
Mr. Lipps continued, “I would like to thank Sara and Vance for their dedication and outstanding contributions to the Board. Over the years, they have provided valuable insights and counsel to support Omnicell in furthering our strategy.”
“Omnicell is at the forefront of delivering mission-critical medication management solutions, and I am honored to join the Board,” said Ms. Voynick. “As hospitals and health systems are relying on technology now more than ever to serve patients, I look forward to leveraging my background in software, healthcare, and operations and working alongside Randall and the rest of the Board as we continue to further our innovation agenda for the benefit of our customers and enhance stockholder value.”
Ms. Voynick has been appointed to the Board’s Corporate Governance Committee. Following the 2024 annual meeting, the Omnicell Board will be comprised of nine directors, eight of whom are independent, and all of whom bring a broad range of expertise and skills necessary to oversee and direct the Company’s business. Six of those independent directors have been added to the Board in the last four years.
